The American Society for Radiation Oncology and the American Academy of Family Physicians have both released recommendations on the diagnosis and treatment of prostate cancer as part of the Choosing Wisely campaign.
The American Society for Radiation Oncology (ASTRO) and the American Academy of Family Physicians (AAFP) have both released recommendations on the diagnosis and treatment of prostate cancer as part of the Choosing Wisely campaign.
The AAFP also weighed in on the use of voiding cystourethrogram in febrile pediatric urinary tract infection.
Choosing Wisely, an initiative of the American Board of Internal Medicine Foundation, is designed to encourage clinicians and patients to scale back medical tests and procedures that may be unnecessary and even potentially harmful. The AUA announced its own recommendations earlier this year.
Among ASTRO’s five items for the initiative were these prostate cancer-related recommendations:
The AAFP’s most recent group of Choosing Wisely recommendations, its third such list, includes a statement reinforcing the organization’s support of the May 2012 recommendation of the U.S. Preventive Services Task Force against performing PSA-based screening for prostate cancer in asymptomatic men.
“For PSA screening in men without symptoms, the data is extremely clear that the test provides very little benefit for patients, along with a significant risk of harm from the diagnostic procedures and the treatments that are performed," said AAFP President-elect Reid Blackwelder, MD.
The AAFP also said physicians should not perform voiding cystourethrogram routinely in first febrile urinary tract infection in children aged 2-24 months. “The risks associated with radiation (plus the discomfort and expense of the procedure) outweigh the risk of delaying the detection of the few children with correctable genitourinary abnormalities until their second UTI,” the AAFP said in a statement.
To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.
Study: Lower PCSM is seen with radical prostatectomy vs other modalities
November 14th 2023"This large registry study with data from varied practice settings, incorporating the most commonly used treatment modalities, provides useful data on the long-term mortality outcomes," writes Badar M. Mian, MD.
Comparing Leuprolide Formulations in Advanced Prostate Cancer
November 13th 2023In the third article of the series, Melanie McGilloway, NP-C, an advanced practice provider at Genesis Urology in San Diego, discusses the various formulations of leuprolide, a gonadotropin-releasing hormone (GnRH) agonist used for treating advanced prostate cancer.